These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26482306)

  • 1. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.
    Thabit AK; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Jan; 60(1):222-8. PubMed ID: 26482306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
    MacVane SH; So W; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7520-6. PubMed ID: 25288076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.
    Hamada Y; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2016 Feb; 60(2):955-61. PubMed ID: 26621619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
    Crandon JL; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5115-9. PubMed ID: 20837760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2928-33. PubMed ID: 19414568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.
    Hagihara M; Wiskirchen DE; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):202-7. PubMed ID: 22006007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
    Leonard SN; Supple ME; Gandhi RG; Patel MD
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
    Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
    Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
    J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.
    Lenhard JR; Brown T; Rybak MJ; Meaney CJ; Norgard NB; Bulman ZP; Brazeau DA; Gill SR; Tsuji BT
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1584-91. PubMed ID: 26711763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.